BridgeMD
RELEASE
EU CTIS ID: 2026-525442-30-00
What this study is testing
To evaluate whether discontinuation of long-term aspirin in patients >65 years with stable chronic coronary syndrome is non-inferior to continued aspirin therapy with respect to net clinical outcome.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- • Age ≥65 years at randomization • Ischemic heart disease with index event (MI, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG)) >2 years previously • Since index event free from ischemic cardiovascular events (MI, ischemic stroke, or transitory ischemic attack) or any coronary revascularization procedure (PCI/CABG) • Currently treated with low dose aspirin (≤150 mg daily, based on prescription fillings and self-reported)
You likely can't join if
- • Any history of ischemic stroke • Active treatment with or indication for anti-coagulant or P2Y12-inhibitor therapy • Indication for antiplatelet treatment other than secondary prevention of ischemic heart disease according to treating physician (i.e. hematological diseases, peripheral artery disease) • Any revascularization procedure for peripheral artery disease • Any history of stent thrombosis or stenting of the left main coronary artery • Other contraindications to aspirin discontinuation according to treating physician • Not being able to understand Danish
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.